A new pharmaceutical candidate Lu AA38466 enters Lundbeck's development pipeline

H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in
clinical development by initiating phase I clinical studies with Lu
AA38466 in order to investigate safety, tolerability and the
pharmacokinetic profile of the drug in humans.

Lu AA38466 is an ion channel modulator and has demonstrated
convincing effects in a number of animal models of neurological
disorders."Focus at Lundbeck Research is to discover innovative compounds that
address unmet needs for patients. Lu AA38466 is an example of a new
generation of compounds with a great potential for treatment of
certain neurological conditions," says Executive Vice President Peter
Høngaard Andersen, Head of Research at Lundbeck.


Lundbeck contacts


Investors:                 Media:

Jacob Tolstrup             Mads Kronborg
Director                   Media Relations
+45 36 43 30 79            +45 36 43 28 51

Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26


Release No 362 - 18 December 2008


About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of
pharmaceuticals for the treatment of psychiatric and neurological
disorders. In 2007, the company's revenue was DKK 11 billion
(approximately EUR 1.5 billion or USD 2.0 billion). The number of
employees is approx. 5,300 globally. For more information, please
visit www.lundbeck.com.